# A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

> **NCT00529373** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 16071 (actual)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** Odanacatib
- **DRUG:** Placebo for Odanacatib
- **DIETARY_SUPPLEMENT:** Vitamin D3
- **DIETARY_SUPPLEMENT:** Calcium carbonate

## Key facts

- **NCT ID:** NCT00529373
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09-13
- **Primary completion:** 2012-11-14
- **Final completion:** 2017-02-01
- **Target enrollment:** 16071 (ACTUAL)
- **Last updated:** 2024-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529373, "A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00529373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*